Actively Recruiting
Calcium Carbonate to Augment Labor Contractions
Led by Weill Medical College of Cornell University · Updated on 2025-10-23
60
Participants Needed
1
Research Sites
54 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators think that calcium carbonate can act as an assistive medication to improve contractions during labor.
CONDITIONS
Official Title
Calcium Carbonate to Augment Labor Contractions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Nulliparas (no prior pregnancy lasting 20 weeks or greater of gestation)
- Gestational age above 36 weeks, at enrollment
- Present for induction or augmentation of labor inclusive of medical indication, elective induction at greater than 39 weeks' gestation, trial of labor after cesarean
- Singleton gestation (a multiple gestation reduced to a singleton, either spontaneously or therapeutically, before 14 0/7 weeks of gestation is acceptable)
- Ability to give informed consent
- Planned to undergo initiation of oxytocin infusion by their maternity care provider
You will not qualify if you...
- Unable to understand or read English
- Presence of tachysystole (more than 5 contractions in 10 minutes averaged over 30 minutes), recurrent variable or late fetal decelerations, and bradycardia in the prior 30 minutes before enrollment
- Non-vertex presenting fetus at enrollment
- Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., placenta previa, vasa previa, active genital herpes infection, previous transmural myomectomy)
- Multi-fetal gestation (twins, triplets, and higher order multiples)
- Known contraindication to taking calcium carbonate including renal calculus, high urine calcium levels, elevated serum calcium, low serum phosphate, achlorhydria, or suspected digoxin toxicity
- Deliveries with fetal chronic and/or pregnancy-related conditions, IUFD (Intra Uterine Fetal Death) or premature < 36 weeks of gestation
- Major fetal anomaly suspected prenatally (expected neonatal intensive care unit admission)
- Suspected alloimmunization (given increased likelihood of neonatal intensive care unit admission)
- Known severe fetal growth restriction (estimated fetal weight <3rd percentile) or abnormal umbilical artery Doppler studies
- Participation in another interventional study affecting labor and delivery or perinatal outcomes
- Known allergic reactions to synthetic oxytocin intravenous solution or to Calcium Carbonate
- Significantly impaired consciousness or executive function (e.g., intubated or sedated)
- Patients treated with calcium channel blockers such as nifedipine or magnesium
- Chronic renal failure and hyperphosphatemia
- Inability to tolerate oral intake (e.g., nausea/vomiting)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Weill Cornell Medicine
New York, New York, United States, 10065
Actively Recruiting
Research Team
E
Ester Sanchez, BSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here